MCID: DBT009
MIFTS: 64

Diabetes Mellitus

Categories: Blood diseases, Endocrine diseases, Genetic diseases, Metabolic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Diabetes Mellitus

MalaCards integrated aliases for Diabetes Mellitus:

Name: Diabetes Mellitus 12 74 29 54 6 43 15 17 71 32
Diabetes 6 42 3 15 39 71

Classifications:



External Ids:

Disease Ontology 12 DOID:9351
ICD9CM 34 250
MeSH 43 D003920
NCIt 49 C2985
SNOMED-CT 67 73211009
UMLS 71 C0011847 C0011849

Summaries for Diabetes Mellitus

MedlinePlus : 42 Diabetes is a disease in which your blood glucose, or blood sugar, levels are too high. Glucose comes from the foods you eat. Insulin is a hormone that helps the glucose get into your cells to give them energy. With type 1 diabetes, your body does not make insulin. With type 2 diabetes, the more common type, your body does not make or use insulin well. Without enough insulin, the glucose stays in your blood. You can also have prediabetes. This means that your blood sugar is higher than normal but not high enough to be called diabetes. Having prediabetes puts you at a higher risk of getting type 2 diabetes. Over time, having too much glucose in your blood can cause serious problems. It can damage your eyes, kidneys, and nerves. Diabetes can also cause heart disease, stroke and even the need to remove a limb. Pregnant women can also get diabetes, called gestational diabetes. Blood tests can show if you have diabetes. One type of test, the A1C, can also check on how you are managing your diabetes. Exercise, weight control and sticking to your meal plan can help control your diabetes. You should also monitor your blood glucose level and take medicine if prescribed. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Diabetes Mellitus, also known as diabetes, is related to maturity-onset diabetes of the young, type 10 and microvascular complications of diabetes 3, and has symptoms including tremor, angina pectoris and equilibration disorder. An important gene associated with Diabetes Mellitus is KCNJ11 (Potassium Inwardly Rectifying Channel Subfamily J Member 11), and among its related pathways/superpathways are MicroRNAs in cancer and Parkinsons Disease Pathway. The drugs Ramipril and Calcium carbonate have been mentioned in the context of this disorder. Affiliated tissues include heart, kidney and endothelial.

Disease Ontology : 12 A glucose metabolism disease characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.

CDC : 3 Diabetes is a chronic (long-lasting) disease that affects how your body turns food into energy. There are three main types of diabetes: type 1, type 2, and gestational diabetes (diabetes while pregnant).

Novus Biologicals : 55 Diabetes is a disease in which the body does not produce or properly use insulin. There are four major types of diabetes: Type 1, Type 2, Gestational and Pre-Diabetes. Type 1 diabetes, previously known as juvenile diabetes, is an autoimmune disease resulting when one's own immune system destroys insulin-producing beta cells in the pancreas. This causes the pancreas to produce little or no insulin. In type 2 diabetes, the body either does not produce enough insulin or beta cells ignore insulin. Gestational diabetes refers to high glucose levels caused by pregnancy. Pre-diabetes is a condition in which blood glucose levels are high, but not high enough for the diagnosis of type 2 diabetes.

Wikipedia : 74 Diabetes mellitus (DM), commonly known as diabetes, is a group of metabolic disorders characterized by a... more...

Related Diseases for Diabetes Mellitus

Diseases in the Diabetes Mellitus family:

Diabetes Mellitus, Congenital Autoimmune Type 1 Diabetes Mellitus 2
Type 1 Diabetes Mellitus 3 Type 1 Diabetes Mellitus 4
Type 1 Diabetes Mellitus 5 Type 1 Diabetes Mellitus 6
Type 1 Diabetes Mellitus 7 Type 1 Diabetes Mellitus 8
Type 1 Diabetes Mellitus 10 Type 1 Diabetes Mellitus 11
Type 1 Diabetes Mellitus 12 Type 1 Diabetes Mellitus 13
Type 1 Diabetes Mellitus 15 Type 1 Diabetes Mellitus 17
Type 1 Diabetes Mellitus 18 Rare Diabetes Mellitus Type 1
Rare Diabetes Mellitus Type 2 Rare Diabetes Mellitus

Diseases related to Diabetes Mellitus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 3578)
# Related Disease Score Top Affiliating Genes
1 maturity-onset diabetes of the young, type 10 35.0 KCNJ11 INS
2 microvascular complications of diabetes 3 33.4 PVT1 MALAT1 INS
3 maturity-onset diabetes of the young, type 4 33.4 KCNJ11 INS
4 non-alcoholic fatty liver disease 33.2 MIR17 MIR140 MIR132 INS
5 acute insulin response 32.2 KCNJ11 INS
6 bile duct disease 32.1 MIR30E MIR17 MIR145 MIR140
7 body mass index quantitative trait locus 11 31.9 MIR30E MIR17 MIR155 MIR140 KCNJ11 INS
8 arteries, anomalies of 31.9 MIR30E MIR17 MIR155 MIR145 MIR140 INS
9 hyperinsulinemic hypoglycemia 31.8 MEN1 KCNJ11 INS
10 hypertension, essential 31.8 MIR17 MIR155 MEN1 KCNJ11 INS CELA2A
11 stomach disease 31.8 MIR99A MIR30E MIR17 MIR145 MIR140
12 coronary heart disease 1 31.6 MIR17 MIR155 MIR145 MIR140 INS CELA2A
13 thyroid gland disease 31.6 MIR30E MIR17 MIR140 INS
14 glucose metabolism disease 31.5 MIR17 MIR155 MIR140 KCNJ11 INS
15 cardiovascular system disease 31.3 MIR17 MIR155 MIR145 INS CDKN2B-AS1
16 overnutrition 31.3 MIR17 MIR155 MIR140 INS
17 asphyxia neonatorum 31.2 KCNJ11 INS
18 gallbladder disease 31.1 MIR17 MIR145 INS
19 colonic disease 31.1 MIR99A MIR30E MIR17 MIR155 MIR145 MIR140
20 pituitary infarct 31.0 MEN1 INS
21 disease of mental health 31.0 MIR17 MIR140 MIR132 INS
22 rectum cancer 30.9 MIR99A MIR17 MIR145
23 pituitary apoplexy 30.8 MEN1 INS
24 connective tissue disease 30.7 MIR30E MIR17 MIR155 MIR140 INS
25 beckwith-wiedemann syndrome 30.7 MEN1 MEG3 KCNJ11 INS
26 prostate disease 30.6 MIR99A MIR30E MIR17 MIR155 MIR145 MEG3
27 thyroid gland papillary carcinoma 30.6 MIR30E MIR17 MIR140
28 pancreas disease 30.6 MIR99A MIR30E MIR17 MIR155 MIR145 MIR140
29 polymyositis 30.5 MIR155 MIR132
30 kidney cancer 30.4 PVT1 MIR17 MEG3 MALAT1 INS
31 pancreatic endocrine carcinoma 30.4 MEN1 MEG3 INS
32 biliary tract disease 30.3 MIR30E MIR17 MIR145 MIR140
33 immune system disease 30.3 MIR17 MIR155 MIR140 INS
34 pituitary adenoma 30.3 MIR197 MIR132 MEN1 MEG3 MALAT1
35 breast disease 30.2 MIR17 MIR155 MIR145 MIR140
36 pancreatic ductal adenocarcinoma 30.2 PVT1 MIR375 MIR155 MIR145 MALAT1
37 lymphoma, hodgkin, classic 30.2 PVT1 MIR155 MIR140
38 bladder disease 30.2 MIR99A MIR17 MIR145 MIR140
39 duodenal somatostatinoma 30.2 MEN1 INS
40 diffuse large b-cell lymphoma 30.2 MIR99A MIR17 MIR155 MIR145
41 gastrointestinal system disease 30.1 MIR99A MIR30E MIR17 MIR155 MIR145 MIR140
42 bone inflammation disease 29.9 MIR17 MIR155 MIR140
43 central nervous system disease 29.9 MIR17 MIR155 MIR140 MIR132
44 b-cell lymphoma 29.8 TUG1 PVT1 MIR17 MIR155 MALAT1
45 neuroblastoma 29.8 MIR99A MIR17 MEN1 MEG3 MALAT1 INS
46 oral cavity cancer 29.8 MIR30E MIR17 MIR145 MIR140
47 hyperpituitarism 29.7 MEN1 INS
48 nervous system disease 29.7 MIR30E MIR17 MIR155 MIR145 MIR140 MIR132
49 muscular dystrophy, duchenne type 29.6 MIR30E MIR197 MIR155 MIR134
50 urinary system disease 29.5 MIR99A MIR30E MIR17 MIR155 MIR145 MIR140

Graphical network of the top 20 diseases related to Diabetes Mellitus:



Diseases related to Diabetes Mellitus

Symptoms & Phenotypes for Diabetes Mellitus

UMLS symptoms related to Diabetes Mellitus:


tremor, angina pectoris, equilibration disorder, symptoms

Drugs & Therapeutics for Diabetes Mellitus

Drugs for Diabetes Mellitus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1009)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ramipril Approved Phase 4 87333-19-5 5362129
2
Calcium carbonate Approved, Investigational Phase 4 471-34-1
3
Methyldopa Approved Phase 4 555-30-6 38853
4
Nicorandil Approved, Investigational Phase 4 65141-46-0 47528
5
Iodine Approved, Investigational Phase 4 7553-56-2 807
6
Povidone Approved Phase 4 9003-39-8
7
Povidone-iodine Approved Phase 4 25655-41-8
8
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
9
Curcumin Approved, Experimental, Investigational Phase 4 458-37-7 969516
10
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
11
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
12
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
13
Succimer Approved Phase 4 304-55-2 9354
14
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
15
Nifedipine Approved Phase 4 21829-25-4 4485
16
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
17
Dimethyl fumarate Approved, Investigational Phase 4 624-49-7 637568 5271565
18
Adalimumab Approved Phase 4 331731-18-1 16219006
19
Thrombin Approved, Investigational Phase 4
20
Pitavastatin Approved Phase 4 147511-69-1, 147526-32-7 6366718 5282452
21
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
22
Gliquidone Approved, Investigational Phase 4 33342-05-1 91610
23
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
24
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
25
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
26
Captopril Approved Phase 4 62571-86-2 44093
27
Tolbutamide Approved, Investigational Phase 4 64-77-7 5505
28
Magnesium oxide Approved Phase 4 1309-48-4 14792
29
Bilberry Approved, Experimental Phase 4
30
Fenofibrate Approved Phase 4 49562-28-9 3339
31
Lacidipine Approved, Investigational Phase 4 103890-78-4
32
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
33
Enalaprilat Approved Phase 4 76420-72-9 6917719
34
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
35
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
36
Rifampicin Approved Phase 4 13292-46-1 5458213 5381226
37
Trimetazidine Approved, Investigational Phase 4 5011-34-7
38
Lactulose Approved Phase 4 4618-18-2 11333
39 Lycopene Approved, Investigational Phase 4 502-65-8 53477748
40
Citalopram Approved Phase 4 59729-33-8 2771
41
Eplerenone Approved Phase 4 107724-20-9 150310 443872
42
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
43
Norepinephrine Approved Phase 4 51-41-2 439260
44
Hydroxychloroquine Approved Phase 4 118-42-3 3652
45
Ranibizumab Approved Phase 4 347396-82-1 459903
46
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
47
Piperacillin Approved Phase 4 66258-76-2 43672
48
Ampicillin Approved, Vet_approved Phase 4 69-53-4 6249
49
Tazobactam Approved Phase 4 89786-04-9 123630
50
Sulbactam Approved Phase 4 68373-14-8

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 Inspiratory Muscle Training in Patients With Autonomic Neuropathic: a Randomized Trial Unknown status NCT00752440 Phase 4
2 Efficacy and Safety of Lobeglitazone Versus Sitagliptin in Inadequately Controlled by Metformin Alone Type 2 Diabetes Mellitus Patients With Metabolic Syndrome: 24-week, Multi-center, Randomized, Double-blind, Phase 4 Study Unknown status NCT02480465 Phase 4 Lobelitazone 0.5mg;Sitagliptin 100mg
3 Real-Time Continuous Glucose Monitoring in Pre-School Children With Type-1 Diabetes Mellitus Unknown status NCT01016457 Phase 4
4 Pharmacodynamics Study to Investigate the Effect of Evogliptin on Bone Metabolism in Healthy Volunteers Unknown status NCT02587975 Phase 4 Evogliptin
5 A Randomized, Controlled Study on Calcium Channel Blocker Versus Angiotensin II Antagonists in the Hypertensive Patients With Type 2 Diabetes Mellitus Under the Inadequately Controlled Blood Pressure With Angiotension II Antagonists Unknown status NCT00144144 Phase 4 Angiotensin II receptor antagonists, Calcium channel blocker
6 A Double-Blind, Randomized, Parallel, Comparative Study to Evaluate the Efficacy and Safety of an Antidiabetic Agent Repaglinide for the Treatment of Type 2 Diabetes Mellitus Patients Unknown status NCT00336310 Phase 4 Repaglinide
7 The Effect of TRADJENTA ® (LINAGLIPTIN) on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects Unknown status NCT02372630 Phase 4 Linagliptin;Placebo
8 Metabolomic Variations in the Saxagliptin-Treated Type 2 Diabetes Mellitus Patients Unknown status NCT01768208 Phase 4 Saxagliptin
9 Aspirin and the Antiproteinuric Effect of Enalapril in Microalbuminuric Type 2 Diabetes Mellitus Patients: a Randomized, Double-Blind, Placebo-Controlled Study Unknown status NCT00427271 Phase 4 aspirin
10 A Randomized, Double-blind, Active Control, Parallel Group, Exploratory Phase IV Study to Compare the Effects of Tenelia® or Januvia® on Glucose Variability in add-on to Metformin in Patients With Inadequately Controlled Type2 Diabetes Mellitus in Metformin Only Treatment Unknown status NCT02512523 Phase 4 Teneligliptin;Sitagliptin
11 Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Overweight and Obesity Patients With Newly Diagnosed Type 2 Diabetes Mellitus: A Randomized Control Study Unknown status NCT02999841 Phase 4 Acarbose;Vildagliptin
12 Multi-Center, Randomized, Open Label Study of the Efficacy of Cilostazol Versus Aspirin for Primary Prevention of Atherosclerotic Events With Korean Type 2 DM Patients Unknown status NCT00886574 Phase 4 Cilostazol;Aspirin
13 Is Insulin NovoRapid Better Than Actrapid for Treating Type 1 Diabetic Patients When Simultaneously, Daily Adjusting the Insulin Dose? Unknown status NCT00145353 Phase 4 Insulin NovoRapid versus Actrapid
14 Prospective Randomized Trials of Gastric Bypass Surgery in Patients With Type II Diabetes Mellitus Unknown status NCT00540462 Phase 4
15 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Unknown status NCT02595606 Phase 4 0.3% Sodium Hyaluronate
16 Metabolism-independent Vascular Effects of the Dipetidylpeptidase-4-inhibitor Sitagliptin in Patients With Type 2 Diabetes Mellitus Unknown status NCT01096277 Phase 4 Sitagliptin;Placebo
17 Effectiveness and Tolerability of Early Initiation of Combined Lipid -Lowering Therapy Included Simvastatin and Fenofibrate vs Simvastatin Alone in Patients With Type 2 Diabetes Mellitus, Hypertriglyceridemia and Acute Coronary Syndrome Unknown status NCT02015988 Phase 4 Fenofibrate;Simvastatin
18 Escitalopram Treatment of Major Depression in Diabetes Mellitus: An Open Label Unknown status NCT00650897 Phase 4 Escitalopram
19 A Randomized Doubleblind Placebo Controlled Crossover Study With Hexalacton in Patients With Type 1 Diabetes and Microalbuminuria Unknown status NCT00843388 Phase 4 Spironolacton (hexalacton(R));placebo tablet
20 Investigation of a Switch From Insulin Therapy to a Metformin & Saxagliptin Combination in Patients With Type 2 Diabetes Mellitus Unknown status NCT01206647 Phase 4 Metformin and Saxagliptin
21 Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy Unknown status NCT01565096 Phase 4 Metformin;Metformin;Vildagliptin;Glimepiride
22 The Effect of Omega-3 Fatty Acids on Hypertriglyceridemia in Patients With Type 2 Diabetes Mellitus Unknown status NCT03120299 Phase 4 Omega-3 fatty acid;Placebos
23 Study on the Efficacy aNd Safety of Jinlida Granules in Patients With Inadequately cOntrolled tYpe-2 Diabetes and dysLIpidemia Under liFe Style Intervention (ENJOY LIFE Study) Unknown status NCT02035644 Phase 4 Jinlida granules;placebo granules
24 Beijing Chao-yang Hospital, Capital Medical University Unknown status NCT02583438 Phase 4 Saxagliptin (Bristol-Myers Squibb Company)
25 Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. Clinical Trial of Low Level of Intervention. (Ineox Study) Unknown status NCT03328845 Phase 4 Toujeo SoloStar;Tresiba;Humalog Kwikpen;NovoRapid;Apidra
26 Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness in Type 2 Diabetes Patient With Metabolic Syndrome (Randomized, Double-Blind, Placebo-Controled, Cross-Over Study) Unknown status NCT00573950 Phase 4 cilostazol;Placebo
27 A Randomized Double-blind Study to Evaluate the Effect of Linagliptin on Pancreatic Beta Cell Function and Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy Unknown status NCT02097342 Phase 4 Linagliptin;Placebo;Voglibose
28 Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus Unknown status NCT01547104 Phase 4 Linagliptin;Glimepiride
29 A Single Arm, Single Dose Study to Evaluate the Effect of Intravitreal Dexamethasone Implant (Ozurdex®) on Hard Exudates of Diabetic Macular Edema Unknown status NCT02399657 Phase 4 Intravitreal dexamethasone 0.7mg implant
30 Effects of New Longacting Insulin Analogs on Metabolic Control, Endogenous Insulin Production, GH/IGF-I Axis and Quality of Life - Comparison of NPH, Glargine Och Detemir Insulin From the Debut of Type 1 Diabetes Mellitus in Adolescents Unknown status NCT01271517 Phase 4 NPH insulin;Glargine;Detemir
31 Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients Unknown status NCT02933788 Phase 4 Cilostazol;Acetylsalicylic acid
32 Basal-bolus Insulin Therapy With Insulin Degludec and Insulin Aspart Versus Standard Therapy for the Inpatient Management of Type 2 Diabetes: the IDA2 Study Unknown status NCT03244241 Phase 4 Insulin Degludec 100 UNT/ML [Tresiba]
33 Immune Intervention With Anti-CD20 Monoclonal Antibody to Preserve Beta Cell Function in Early Onset Type 1 Diabetes Unknown status NCT01280682 Phase 4 rituximab
34 Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes: Study of Insulin Sensitivity in the 2 Types of Treatment Unknown status NCT02048189 Phase 4 LEVEMIR;APIDRA
35 An Open-label, Randomized, Active-controlled Study to Compare the Effect of DPP-IV Inhibitor and TZD as add-on Therapy to Metformin on Glycemic Variability and Oxidative Stress in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy Unknown status NCT01339143 Phase 4 Galvus (vildagliptin);pioglitazone
36 Safety of Add on Aliskiren to ACEI and ARB Treatment in Type 2 Diabetes With Nephropathy Unknown status NCT00949351 Phase 4 Aliskiren 300mg/d
37 Efficacy of Combination of Glucometer and Mobile-phone Based Data Transfer System on Glycemic Control in Patients With Diabetes Unknown status NCT02769377 Phase 4
38 A Randomized, Open, Controlled, Parallel Group Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin Therapy Unknown status NCT03320031 Phase 4 Linagliptin;Humalog Mix 75/25
39 Effect of Allopurinol on Mono and Co-administration With Statins on Platelets Reactivity on Diabetic Patiets Treated With Aspirin and Insulin Unknown status NCT03195153 Phase 4 Atorvastatin 80mg;ALLOPURINOL 300 MG;Atorvastatin 80mg AND allopurinol 300 mg
40 Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2 Unknown status NCT00473733 Phase 4
41 The Reduction of Microalbuminuria in Japanese Hypertensive Subjects With Type 2 Diabetes Mellitus Treated With Valsartan or Amlodipine: Study Design for the Shiga Microalbuminuria Reduction Trial (SMART) Unknown status NCT00202618 Phase 4 Valsartan;Amlodipine
42 Multicenter Trial on Clinical Utility of Acarbose in Patients With Ischemic Heart Disease Accompanied by Abnormal Glucose Regulation Unknown status NCT00858676 Phase 4 acarbose
43 Effect of Reconstitute Multiple Grain on Glucose and Lipid Metabolism in Patients With Type 2 Diabetes Unknown status NCT00337337 Phase 4
44 Improving Glycaemic Control in Malaysian Patients With Type 2 Diabetes Mellitus With Insulin Pump Therapy Unknown status NCT03112538 Phase 4 Multiple daily injections of insulin
45 A 24-Week, National, Single-Centre, Open-Labelled, Randomised, Parallel-Group Trial Comparing Energy Expenditure With Insulin Detemir Versus NPH Insulin Using a Basal-Bolus Regimen With Insulin Aspart as the Mealtime Insulin in Subjects With Type 2 Diabetes Unknown status NCT00788840 Phase 4 Insulatard;Detemir
46 Effect of Androgel on Inflammatory Mediators and Oxidative Stress in Type 2 Diabetic Males With Hypogonadism Unknown status NCT00350701 Phase 4 androgel;androgel 10g;placebo
47 the Effect of Vitamin D on the Serum Thioredoxin, TBP-2, Thioredoxin Reductase, Gene Expression of TBP-2 in Patients With Type II Diabetes Unknown status NCT01876563 Phase 4
48 A Randomized, Non-inferiority, Open-label Clinical Trial to Evaluate the Safety and Efficacy of GAcarbose+Saxagliptin Compared With Metformin+Saxagliptin in Patients With Type 2 Diabetes in Chinese Unknown status NCT02605772 Phase 4 Acarbose;Metformin;Saxagliptin
49 Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI:Effects on Oxidative Stress and Inflammation. Unknown status NCT00430040 Phase 4 carvedilol;lisinopril
50 Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension Unknown status NCT00407680 Phase 4 Intensive therapy Valsartan,Fluvastatin

Search NIH Clinical Center for Diabetes Mellitus

Inferred drug relations via UMLS 71 / NDF-RT 50 :


CHROMIUM PICOLINATE

Cochrane evidence based reviews: diabetes mellitus

Genetic Tests for Diabetes Mellitus

Genetic tests related to Diabetes Mellitus:

# Genetic test Affiliating Genes
1 Diabetes Mellitus 29

Anatomical Context for Diabetes Mellitus

MalaCards organs/tissues related to Diabetes Mellitus:

40
Heart, Kidney, Endothelial, Testes, Liver, Bone, Pancreas

Publications for Diabetes Mellitus

Articles related to Diabetes Mellitus:

(show top 50) (show all 52554)
# Title Authors PMID Year
1
Elevated Cardiometabolic Risk Profile Among Young Adults With Diabetes: Need for Action. 42
31540959 2019
2
Influence of hypercholesterolemia and diabetes on long-term outcome in patients with stable coronary artery disease receiving percutaneous coronary intervention. 42
31441878 2019
3
Risk strata and quality of care for the elderly in Primary Health Care. 42
31596406 2019
4
Plasma copeptin and the risk of diabetes mellitus. 54 61
20439785 2010
5
CTLA4 promoter polymorphisms are associated with canine diabetes mellitus. 54 61
20196832 2010
6
[A target of PPARgamma agonist: diabetes mellitus]. 54 61
20158098 2010
7
[Diabetes susceptibility genes]. 54 61
19507498 2009
8
MicroRNA expression in human omental and subcutaneous adipose tissue. 46
19259271 2009
9
Autoantibodies to GAD65 and IA-2 in canine diabetes mellitus. 54 61
18706702 2008
10
Monocyte attachment and migration through collagen IV in diabetes mellitus. 54 61
18443419 2008
11
Gene polymorphisms of superoxide dismutases and catalase in diabetes mellitus. 54 61
18423055 2008
12
Testing of diabetes-associated WFS1 polymorphisms in the Diabetes Prevention Program. 54 61
18060660 2008
13
N-acetyltransferase 2 polymorphism in patients with diabetes mellitus. 54 61
16397907 2007
14
HNF4A genetic variants: role in diabetes. 54 61
17563455 2007
15
Evaluation of inhaled insulin therapy for diabetes mellitus. 54 61
17703168 2007
16
Diabetes beyond insulin: review of new drugs for treatment of diabetes mellitus. 54 61
17630927 2007
17
Insulin analogues: new dimension of management of diabetes mellitus. 54 61
17344794 2007
18
[Antihypertensive agents and the risk of new onset diabetes mellitus]. 54 61
17212194 2006
19
[Aceruloplasminemia (hereditary ceruloplasmin deficiency) and diabetes mellitus]. 54 61
17022509 2006
20
Estrogen receptors: new players in diabetes mellitus. 54 61
16890492 2006
21
[Calcium homeostasis and diabetes mellitus]. 54 61
16883034 2006
22
Diabetes, nephropathy, and the renin system. 54 61
16601578 2006
23
Reactive oxygen species, hydrogen peroxide, catalase and diabetes mellitus. 54 61
17207310 2006
24
Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus. 54 61
16442340 2006
25
Calpain 10 and development of diabetes mellitus in cystic fibrosis. 54 61
16377260 2006
26
Oxidative inactivation of paraoxonase--implications in diabetes mellitus and atherosclerosis. 54 61
16112460 2005
27
Diabetes mellitus following pituitary adenomectomy in euglycemic patients with acromegaly. 54 61
16197874 2005
28
Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. 54 61
15864535 2005
29
Glucokinase, glucose homeostasis, and diabetes mellitus. 54 61
15929862 2005
30
[Association of urotensin II and diabetes mellitus and kidney diseases]. 54 61
16061011 2005
31
[PPARgamma gene Pro12Ala polymorphism in diabetes mellitus]. 54 61
15779363 2005
32
'Human' insulin versus animal insulin in people with diabetes mellitus. 54 61
15674916 2005
33
PON1 polymorphism, diabetes mellitus, obesity, and risk of myocardial infarction: Modifying effect of diabetes mellitus and obesity on the association between PON1 polymorphism and myocardial infarction. 54 61
15654230 2005
34
A pancreatic islet-specific microRNA regulates insulin secretion. 46
15538371 2004
35
Diabetes mellitus has an additional effect on coronary artery disease. 54 61
15655267 2004
36
IGF-I in mammary tumorigenesis and diabetes. 54 61
15517902 2004
37
Molecular changes in proximal tubule function in diabetes mellitus. 54 61
15191416 2004
38
Brain naturetic peptide (BNP) and diabetes mellitus. 54 61
15089779 2004
39
Diabetes, lipids, and adipocyte secretagogues. 54 61
15052336 2004
40
Diabetes mellitus in Tropical Chronic Pancreatitis Is Not Just a Secondary Type of Diabetes. 54 61
15258409 2004
41
Alveolar gas exchange in patients with type 2 diabetes mellitus. 54 61
14709835 2003
42
Transferrin modifications and lipid peroxidation: implications in diabetes mellitus. 54 61
14703796 2003
43
[Significance of renin-angiotensin system in diabetes mellitus with hypertension]. 54 61
12877076 2003
44
Diabetes mellitus, insulin, and melioidosis in Thailand. 54 61
12594658 2003
45
'Human' insulin versus animal insulin in people with diabetes mellitus. 54 61
12917989 2003
46
[Leptin levels in patients with bronchial asthma and diabetes mellitus]. 54 61
12718213 2003
47
Elevated plasma endothelin-1 levels in diabetes mellitus. 54 61
12441216 2002
48
Lipoprotein lipase deficiency and transient diabetes mellitus in a neonate. 54 61
12408192 2002
49
Leptin levels in children with insulin dependent diabetes mellitus. 54 61
12405431 2002
50
Obesity: a rational target for managing diabetes mellitus. 54 61
11527093 2001

Variations for Diabetes Mellitus

ClinVar genetic disease variations for Diabetes Mellitus:

6 (show all 14) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 KCNJ11 NM_000525.3(KCNJ11):c.988T>C (p.Tyr330His)SNV Pathogenic 158688 rs587783675 11:17408651-17408651 11:17387104-17387104
2 KCNJ11 NM_000525.3(KCNJ11):c.685G>A (p.Glu229Lys)SNV Pathogenic 158683 rs587783673 11:17408954-17408954 11:17387407-17387407
3 KCNJ11 NM_000525.3(KCNJ11):c.679G>A (p.Glu227Lys)SNV Pathogenic 158682 rs587783672 11:17408960-17408960 11:17387413-17387413
4 MEN1 NM_000244.3(MEN1):c.669+1deldeletion Pathogenic 374107 rs1057518903 11:64575362-64575362 11:64807890-64807890
5 CELA2A NM_033440.3(CELA2A):c.209C>T (p.Thr70Met)SNV Pathogenic 633595 1:15788135-15788135 1:15461640-15461640
6 CELA2A NM_033440.3(CELA2A):c.253C>A (p.Leu85Met)SNV Pathogenic 633593 1:15789253-15789253 1:15462758-15462758
7 CELA2A NM_033440.3(CELA2A):c.361G>A (p.Asp121Asn)SNV Pathogenic 633592 1:15789885-15789885 1:15463390-15463390
8 CELA2A NM_033440.3(CELA2A):c.639+1G>CSNV Pathogenic 633594 1:15792640-15792640 1:15466145-15466145
9 KCNJ11 NM_000525.3(KCNJ11):c.601C>T (p.Arg201Cys)SNV Pathogenic 8668 rs80356625 11:17409038-17409038 11:17387491-17387491
10 KCNJ11 NM_000525.3(KCNJ11):c.964G>A (p.Glu322Lys)SNV Pathogenic 21203 rs193929355 11:17408675-17408675 11:17387128-17387128
11 KCNJ11 NM_000525.3(KCNJ11):c.498C>G (p.Cys166Trp)SNV Likely pathogenic 158676 rs587783669 11:17409141-17409141 11:17387594-17387594
12 ABCC8 NM_001287174.2(ABCC8):c.1562G>A (p.Arg521Gln)SNV Conflicting interpretations of pathogenicity 157683 rs368114790 11:17464335-17464335 11:17442788-17442788
13 CEL NM_001807.5(CEL):c.1966G>C (p.Ala656Pro)SNV Uncertain significance 128688 rs587780309 9:135946855-135946855 9:133071468-133071468
14 KCNJ11 NM_000525.3(KCNJ11):c.463G>A (p.Val155Met)SNV Uncertain significance 158675 rs587783668 11:17409176-17409176 11:17387629-17387629

Copy number variations for Diabetes Mellitus from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 110220 17 3154257 3410803 Deletion HNF1b Diabetes mellitus
2 110369 17 31923035 33323544 Deletion HNF1B Diabetes mellitus
3 110541 17 33120546 33179209 Deletion HNF1B Diabetes mellitus
4 203632 1 158846514 158883705 Rearrangement SLAM Diabetes mellitus
5 225144 7 43300000 45400000 Gain or loss GCK Diabetes mellitus

Expression for Diabetes Mellitus

Search GEO for disease gene expression data for Diabetes Mellitus.

Pathways for Diabetes Mellitus

Pathways related to Diabetes Mellitus according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.59 MIR99A MIR375 MIR30E MIR17 MIR155 MIR145
2 11.18 MIR375 MIR30E MIR17 MIR132

GO Terms for Diabetes Mellitus

Cellular components related to Diabetes Mellitus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.36 MIR99A MIR375 MIR30E MIR197 MIR17 MIR155

Biological processes related to Diabetes Mellitus according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.73 MIR17 MIR155 MIR132 CDKN2B-AS1
2 positive regulation of gene expression GO:0010628 9.72 MIR155 MIR140 MIR132 INS CDKN2B-AS1
3 cellular response to hypoxia GO:0071456 9.56 MIR17 MIR155 MIR140 MALAT1
4 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.49 MIR17 MIR155
5 fatty acid homeostasis GO:0055089 9.48 MIR132 INS
6 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.46 MIR17 MIR155
7 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.4 MIR17 MIR155
8 negative regulation of interleukin-8 production GO:0032717 9.37 MIR155 MIR132
9 miRNA mediated inhibition of translation GO:0035278 9.35 MIR17 MIR155 MIR145 MIR134 MIR132
10 negative regulation of sprouting angiogenesis GO:1903671 9.33 MIR375 MIR30E MIR17
11 gene silencing by miRNA GO:0035195 9.17 MIR99A MIR30E MIR17 MIR155 MIR145 MIR140

Molecular functions related to Diabetes Mellitus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.23 MIR99A MIR30E MIR17 MIR155 MIR145 MIR140
2 RNA polymerase II complex binding GO:0000993 9.13 MIR375 MIR145 MIR140

Sources for Diabetes Mellitus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....